SAVE THE DATE! The 6th World Consensus Conference on BIA-ALCL will be held April 11-12, 2025, and will feature leading experts in breast surgery and implant safety discussing the latest research on breast implant-associated cancers.

Women with breast implants have long reported lingering health issues—even after removal. Now, groundbreaking research reveals a possible culprit: residual silicone particles left behind in the body, triggering chronic inflammation. Could this be the missing link to unexplained symptoms? Here’s what you need to know.

The FDA plays a major role in deciding which medical devices are safe, but who ensures that patient voices are heard in those decisions? BISA’s own Maria Gmitro has been appointed as a Consumer Representative for the FDA, bringing real-world patient perspectives to the table. Read on to find out why this is a major win for patient advocacy!

Recognized on February 13th, Breast Implant Illness (BII) Awareness Day serves as a critical moment to highlight the struggles faced by individuals experiencing health complications related to breast implants.

On February 6, 2025, the FDA provided updates on the safety and effectiveness of breast implants. BISA provides a brief summary and why this info is crucial for the public.

The FDA recently removed web pages about diversity in clinical trials, medical device safety, and more. Many experts are worried that this will make it harder for people to find important health information.

Are breast implants as safe as we think, and why do we still question the safety? Members of the Breast Implant Safety Alliance (BISA) reviewed a new article examining the reputation of the FDA concerning the safety of breast implants.

BISA’s president Maria Gmitro and BISA’s advisor data advocate Madris Kinard of Device Events were both quoted in MedTech Dive, citing the optimism regarding Dr. Michelle Tarver’s appointment as the new Director of CDRH at FDA.